PUMA BIOTECHNOLOGY, INC. (PBYI) Profit Margins
Over the twelve months to 2026-06-30, PUMA BIOTECHNOLOGY, INC. (PBYI) had gross margin 74.8%, operating margin 13.2%, net margin 11.6%, free cash flow margin 17.8%, according to EquiReason's reading of its SEC filings.
Source: SEC EDGAR filings · figures as of 2026-06-30 · read by EquiReason
PBYIPUMA BIOTECHNOLOGY, INC.Follow PBYI — free
—
Price chart with a free account
- Market cap
- 568.9M
- P/E TTM
- 21.2
- Dividend yield
- —
- 52-week
- —
- Next earnings
- 29 Oct, in 5 days
| Line | FY2017 Dec 17 | FY2018 Dec 18 | FY2019 Dec 19 | FY2020 Dec 20 | FY2021 Dec 21 | FY2022 Dec 22 | FY2023 Dec 23 | FY2024 Dec 24 | FY2025 Dec 25 | TTM Jun 26 | Trend |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross margin | 79.9% | 86.2% | 86.5% | 82.5% | 74.8% | 75.8% | 73.4% | 72.1% | 74.5% | 74.8% | |
| Operating margin | -1056.1% | -37.7% | -14.3% | -13.5% | 0.5% | 10.4% | 13.9% | 13.4% | 16.3% | 13.2% | |
| Net margin | -1054.6% | -45.3% | -27.8% | -26.7% | -11.5% | 0.0% | 9.2% | 13.1% | 13.6% | 11.6% | |
| FCF margin | -624.5% | -9.8% | 8.1% | 0.3% | 8.2% | -6.9% | 11.4% | 16.9% | 18.3% | 17.8% |
USD millions · SEC XBRL
PUMA BIOTECHNOLOGY, INC. — questions
- What is PUMA BIOTECHNOLOGY, INC.'s gross margin?
- 74.8% over the twelve months to 2026-06-30.
- What is PUMA BIOTECHNOLOGY, INC.'s operating margin?
- 13.2% over the twelve months to 2026-06-30.
- What is PUMA BIOTECHNOLOGY, INC.'s net profit margin?
- 11.6% over the twelve months to 2026-06-30.
Every figure on this page comes from PUMA BIOTECHNOLOGY, INC.'s own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.
How these figures are read: methodology · EquiReason.